Evidence map›Paper›PMID 37284893›Full record

ArticleApplied microbiology and biotechnology2023

Isolation and characterization of a VHH targeting the Acinetobacter baumannii cell surface protein CsuA/B.

Eric K Lei, Shannon Ryan, Henk van Faassen, Mary Foss, Anna Robotham, Isabel Baltat, Kelly Fulton, Kevin A Henry, Wangxue Chen, Greg Hussack

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Eric K LeiHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Shannon RyanHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Henk van FaassenHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Mary FossHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Anna RobothamHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Isabel BaltatHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Kelly FultonHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Kevin A HenryHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Wangxue ChenHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.ORCID https://orcid.org/0000-0003-0958-7728
Greg HussackHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada. Greg.Hussack@nrc-cnrc.gc.ca.ORCID http://orcid.org/0000-0002-9852-6865
National Research Council Canada · CABrock University · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acinetobacter baumannii is a Gram-negative bacterial pathogen that exhibits high intrinsic resistance to antimicrobials, with treatment often requiring the use of last-resort antibiotics. Antibiotic-resistant strains have become increasingly prevalent, underscoring a need for new therapeutic interventions. The aim of this study was to use A. baumannii outer membrane vesicles as immunogens to generate single-domain antibodies (VHHs) against bacterial cell surface targets. Llama immunization with the outer membrane vesicle preparations from four A. baumannii strains (ATCC 19606, ATCC 17961, ATCC 17975, and LAC-4) elicited a strong heavy-chain IgG response, and VHHs were selected against cell surface and/or extracellular targets. For one VHH, OMV81, the target antigen was identified using a combination of gel electrophoresis, mass spectrometry, and binding studies. Using these techniques, OMV81 was shown to specifically recognize CsuA/B, a protein subunit of the Csu pilus, with an equilibrium dissociation constant of 17 nM. OMV81 specifically bound to intact A. baumannii cells, highlighting its potential use as a targeting agent. We anticipate the ability to generate antigen-specific antibodies against cell surface A. baumannii targets could provide tools for further study and treatment of this pathogen. KEY POINTS: •Llama immunization with bacterial OMV preparations for VHH generation •A. baumannii CsuA/B, a pilus subunit, identified by mass spectrometry as VHH target •High-affinity and specific VHH binding to CsuA/B and A. baumannii cells.

Indexed as

Acinetobacter baumanniiCamelids, New WorldAnimalsAnti-Bacterial AgentsCell MembraneMembrane ProteinsAnti-Bacterial AgentsMembrane ProteinsAcinetobacter baumanniiAntimicrobial resistanceCsuA/BNanobodyOuter membrane vesiclePilusSingle-domain antibodyVHH

Identifiers

PMID37284893
PMCPMC10246537
OpenAlexW4379598770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.